Generic Name and Formulations:
Hydroquinone 4%, fluocinolone acetonide 0.01%, tretinoin 0.05%; crm; contains sulfites, parabens.
Galderma Laboratories, Inc.
- The Positives of Publishing Negatives: Are Researchers Obligated to Share Negative Trial Results?
- Trick-or-Treating Pedestrian Fatalities: Awareness, Safety Interventions Can Reduce Risks
- High Cost of Clinical Trials Under FDA Pediatric Exclusivity Program Examined
Indications for TRI-LUMA:
Short-term intermittent treatment of moderate to severe melasma of the face, with measures for sun avoidance including sunscreen use (SPF 30).
Clean (use a mild, soap-free cleanser) and dry skin. Apply a thin film to affected area(s) and to ½ inch of surrounding normal skin once daily, at least 30 minutes before bedtime.
Do not occlude or use on eczema or sunburned skin. Avoid eyes, ears, mouth, angle of nose, mucous membranes, sun, UV light. Skin types V and VI (possible undesirable excessive bleaching). Discontinue if ochronosis, chemical irritation, hypersensitivity, or HPA axis suppression occurs. Increased irritation in extreme weather. Elderly. Pregnancy (Cat.C), nursing mothers: consider delaying use until after pregnancy/nursing.
Skin depigmenting agent + topical steroid + retinoid.
Avoid photosensitizers, topical irritants, and drying agents.
Local irritation (erythema, peeling, burning, dryness, pruritus), acne, paresthesia, telangiectasia, hyperesthesia, folliculitis, dermatitis, secondary infection, hypertrichosis, skin atrophy, striae, miliaria, HPA axis suppression.